Keynote review: In vitro safety pharmacology profiling: An essential tool for successful drug development

Drug Discovery Today

Volumn 10, Issue 21, 2005, Pages 1421-1433

  Whitebread, Steven ^a,c,d   Hamon, Jacques ^a,b,c,d   Bojanic, Dejan ^a   Urban, Laszlo ^a,c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Discovery Technologies   (Switzerland)

^c PreClinical Profiling   (United States)

^d Profiling Group   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL] CYCLOHEXYLMETHYL]AMIDE; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ASTEMIZOLE; BEPRIDIL; CARDIOVASCULAR AGENT; CELERA; CENTRAL NERVOUS SYSTEM AGENTS; CISAPRIDE; DIURETIC AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DROPERIDOL; GREPAFLOXACIN; KETOTIFEN; LEVACETYLMETHADOL; NEUROLEPTIC AGENT; NEW DRUG; NORFENFLURAMINE; OXATOMIDE; ROFECOXIB; SERTINDOLE; SODIUM CHANNEL BLOCKING AGENT; STEROID; TACHYKININ RECEPTOR ANTAGONIST; TERFENADINE; TERODILINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ADDISON DISEASE; ADRENERGIC ACTIVITY; AGRANULOCYTOSIS; AIRWAY OBSTRUCTION; ALLODYNIA; ALOPECIA; ANEMIA; ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; ATTENTION DEFICIT DISORDER; BLADDER DISEASE; BLEEDING; BONE MARROW TOXICITY; BRADYCARDIA; BRONCHOSPASM; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; COLOR VISION DEFECT; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; CORNEA OPACITY; COUGHING; DELIRIUM; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DOPAMINERGIC ACTIVITY; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSKINESIA; ECZEMA; ENTEROPATHY; EOSINOPHILIA; ERECTILE DYSFUNCTION; ERYTHEMA; EXTRAPYRAMIDAL SYNDROME; GALACTORRHEA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GLAUCOMA; GYNECOMASTIA; HALLUCINATION; HEARING IMPAIRMENT; HEART ARREST; HEART ARRHYTHMIA; HEART BLOCK; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART VENTRICLE FIBRILLATION; HEMOLYTIC ANEMIA; HETEROTOPIA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNE DEFICIENCY; INFLAMMATION; INOTROPISM; KIDNEY DISEASE; KIDNEY TUBULE NECROSIS; LIVER TOXICITY; LUNG EDEMA; LUNG INFILTRATE; MEGALOBLASTIC ANEMIA; MEMORY DISORDER; METABOLIC ACIDOSIS; MOTOR COORDINATION; MOTOR DYSFUNCTION; MUSCLE HYPOTONIA; MYALGIA; MYOPATHY; NAUSEA; NEPHRITIS; NEPHROLITHIASIS; NEPHROSIS; NERVE DEGENERATION; NOCICEPTION; NONHUMAN; NOSE CONGESTION; OPTIC NERVE DISEASE; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PANCREAS DISEASE; PANCREATITIS; PANCYTOPENIA; PARANOIA; PARKINSONISM; PERICARDITIS; PERIPHERAL NEUROPATHY; PHOTODERMATOSIS; PREDICTION; PSYCHOSIS; QT PROLONGATION; RENOVASCULAR DISEASE; RESPIRATION DEPRESSION; RETINOPATHY; REVIEW; RHABDOMYOLYSIS; SALIVATION DISORDER; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SMOOTH MUSCLE SPASM; STOMACH DISEASE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THYROID DISEASE; TORSADE DES POINTES; TOXIC HEPATITIS; TREMOR; URTICARIA; VALVULAR HEART DISEASE; VASOCONSTRICTION; VESTIBULAR DISORDER; VISUAL DISORDER; VOMITING; XEROSTOMIA;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY; TOXICITY TESTS;

EID: 26944446576     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03632-9     Document Type: Review

References (62)

1. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev. Drug Discov. 3 2004 711 715
2. Bass A.S. New preclinical guidelines on drug effects on ventricular repolarisation: safety pharmacology comes of age J. Pharmacol. Toxicol. Methods 49 2004 153 158
3. Pugsley M.K. An overview of some pharmacological methods used in safety pharmacology studies Proc. West. Pharmacol. Soc. 47 2004 18 22
4. Williams P.D. The role of pharmacological profiling in safety assessment Regul. Toxicol. Pharmacol. 12 1990 238 252
5. Krejsa C.M. Predicting ADME properties and side effects: The BioPrint approach Curr. Opin. Drug Discov. Devel. 6 2003 470 480
6. Rockman H.A. Seven-transmembrane-spanning receptors and heart function Nature 415 2002 206 212
7. Snodin D.J. An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology Toxicol. Lett. 127 2002 161 168
8. Andersen B.B. Phenytoin-loading: pharmacokinetic comparison between an intravenous bolus injection and a diluted standard solution Acta Neurol. Scand. 85 1992 174 176
9. Rockman H.A. Seven-transmembrane-spanning receptors and heart function Nature 415 2002 206 212
10. Singh B.N. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact Eur. Heart J. 14 Suppl. H 1993 14 23
11. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico Drug Discov. Today 9 2004 276 285
12. Fitzgerald L.W. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine Mol. Pharmacol. 57 2000 75 81
13. Flordellis C. Pharmacogenomics of adrenoceptors Pharmacogenomics 5 2004 803 817
14. Hoyer D., Martin G.R. Classification and nomenclature of 5-HT receptors: a comment on current issues Behav. Brain Res. 73 1996 263 268
15. Gotti C. Drugs selective for nicotinic receptor subtypes: a real possibility or a dream? Behav Brain Res. 113 2000 183 192
16. Dwoskin L.P., Crooks P.A. Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery J. Pharmacol. Exp. Ther. 298 2001 395 402
17. Sher E. Physiological roles of neuronal nicotinic receptor subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity Curr. Top. Med. Chem. 4 2004 283 297
18. Crumb W., Cavero I. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development Pharm. Sci. Technol. Today 2 1999 270 280
19. Netzer R. HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery Curr. Opin. Drug Discov. Devel. 6 2003 462 469
20. Testai L. Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac hERG potassium channels Curr. Med. Chem. 11 2004 2691 2706
21. Cavalli A. Toward the pharmacophore for drugs including the long QT syndrome: insights from a CoMFA study of hERG K+ channel blockers J. Med. Chem. 45 2002 3844 3853
22. Mitcheson J.S., Perry M.D. Molecular determinants of high-affinity drug binding to HERG channels Curr. Opin. Drug Discov. Devel. 6 2003 667 674
23. Oprea T.I., Matter H. Integrating virtual screening in lead discovery Curr. Opin. Chem. Biol. 8 2004 349 358
24. Snider R.M. A potent nonpeptide antagonist of the substance P (NK1) receptor Science 251 1991 435 437
25. Handschin C., Meyer U.A. Induction of drug metabolism: the role of nuclear receptors Pharmacol. Rev. 55 2003 649 673
26. Sonoda J. A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection Curr. Drug Metab. 4 2003 59 72
27. Walsh G.M. Emerging safety issues regarding long-term usage of H(1)receptor antagonists Expert Opin. Drug Saf. 1 2002 225 235
28. Salib R.J., Horwath P.H. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis Drug Saf. 26 2003 863 893
29. Simons F.E.R. H1-Antihistamines: more relevant than ever in the treatment of allergic disorders J. Allergy Clin. Immunol. 112 Suppl. 4 2003 S42 S52
30. Gani F. Rhinitis in pregnancy Allerg. Immunol. 35 2003 306 313
31. Suessbrich H. Blockade of hERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole FEBS Lett. 385 1996 77 80
32. Woosley R.L. Cardiac actions of antihistamines Annu. Rev. Pharmacol. Toxicol. 36 1996 233 252
33. Taglialatela M. The molecular basis for the lack of hERG K+ channels block-related cardiotoxicity by the H1 receptor blocker cetirizine as compared to other second-generation antihistamines Mol. Pharmacol. 54 1998 113 121
34. Passalacqua G. The clinical safety of H1-receptor antagonists An EAACI position paper. Allergy 51 1996 666 675
35. Simons F.E.R. Non-cardiac adverse effects of antihistamines (H1 receptor antagonists) Clin. Exp. Allergy 29 1999 125 132
36. Rueeger H. Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-1-aza-benzo[e]azulen-derivatives as neuropeptide Y Y5 receptor antagonists Bioorg. Med. Chem. Lett. 14 2004 2451 2457
37. Criscione L. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor J. Clin. Invest. 102 1998 2136 2145
38. Della Zuana O. Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade Int. J. Obes. 25 2001 84 94
39. Kanatani A. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice Endocrinology 141 2000 1011 1016
40. Dryden S. The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats Neuroscience 72 1996 557 566
41. Wellman P.J. Modulation of feeding by hypothalamic paraventricular nucleus alpha-1 and alpha-2 adrenergic receptors Life Sci. 53 1993 669 679
42. Hagan M.M. The effect of hypothalamic peptide YY on hippocampal acetylcholine release in vivo: implications for limbic function in binge-eating behavior Brain Res. 805 1998 20 28
43. Regoli D. B1 and B2 kinin receptors in various species Immunopharmacology 36 1997 143 147
44. Burgess G.M. Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia Br. J. Pharmacol. 129 2000 77 86
45. Waldman S.A. Does potency predict clinical efficacy? Illustration through an antihistamine model Ann. Allergy Asthma Immunol. 89 2002 7 11
46. Wang J., Urban L. The Impact of Early ADME Profiling on Drug Discovery and Development Strategy Drug Discov. Word 5 2004 73 86
47. Podlogar B.L. Computational methods to estimate drug development parameters Curr. Opin. Drug Discov. Devel. 4 2001 102 109
48. Mitchell T., Showell G.A. Design strategies to build drug-like chemical libraries Curr. Opin. Drug Discov. Devel. 4 2001 314 318
49. Feuston B.P. Comparison of knowledge-based and distance geometry approaches for generation of molecular conformations J. Chem. Inf. Comput. Sci. 41 2001 754 763
50. So S.S., Karplus M. Evolutionary optimization in quantitative structure activity relationship: An application of genetic neural networks J. Med. Chem. 39 1996 1521 1530
51. Patterson D.E. Neighborhood behavior: A useful concept for validation of "molecular Diversity" descriptors J. Med. Chem. 39 1996 3049 3059
52. Horvath D. ComPharm - Automated comparative analysis of pharmacophoric patterns and derived QASAR approaches, novel tools in high throughput drug discovery. A proof of concept study applied to farnesyl protein transferase inhibitor design Diudea M. QSPAR/QASAR Studies by Molecular Descriptors 2001 Nova Science Publishers 395 439
53. Artursson P. Caco-2 monolayers in experimental and theoretical predictions of drug transport Adv. Drug Deliv. Rev. 46 2001 27 43
54. Davies N.M., Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter J. Pharm. Pharm. Sci. 7 2004 332 336
55. Carne X., Cruz N. Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib) Eur. J. Epidemiol. 20 2005 127 129
56. Juni P. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis Lancet 364 2004 2021 2029
57. Mukherjee D. Risk of cardiovascular events associated with selective COX-2 inhibitors J. Am. Med. Assoc. 286 2001 954 959
58. Witchel H.J. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram (Celera) on HERG and ventricular L-type calcium currents FEBS Lett. 512 2002 59 66
59. Lee K. IKr channel blockers: novel antiarrhythmic agents Curr. Med. Chem. Cardiovasc. Hematol. Agents 1 2003 203 223
60. Roth B.L. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discov. 3 2004 353 359
61. Klabunde T., Hessler G. Drug design strategies for targeting G-protein-coupled receptors ChemBioChem 3 2002 928 944
62. Kinter L.B. Status of Safety Pharmacology in the Pharmaceutical Industry-1993 Drug Dev. Res. 32 1994 208 216